Signaturefd LLC Purchases 8,035 Shares of GSK plc (NYSE:GSK)

Signaturefd LLC raised its stake in shares of GSK plc (NYSE:GSK - Free Report) by 25.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,090 shares of the pharmaceutical company's stock after purchasing an additional 8,035 shares during the quarter. Signaturefd LLC's holdings in GSK were worth $1,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. FMR LLC raised its stake in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC raised its stake in shares of GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock worth $16,747,000 after acquiring an additional 51,378 shares in the last quarter. Cerity Partners LLC raised its stake in shares of GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock worth $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC raised its stake in shares of GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock worth $20,460,000 after acquiring an additional 83,433 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts recently commented on GSK shares. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Trading Down 0.5 %

GSK stock traded down $0.19 during mid-day trading on Friday, reaching $39.22. 4,020,576 shares of the company traded hands, compared to its average volume of 4,334,257. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm's 50 day moving average price is $36.66 and its 200 day moving average price is $36.97. The firm has a market capitalization of $81.18 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.93.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.